Molecular analysis of inflammatory markers in trauma patients at risk of postinjury complications

Journal of Trauma - Injury, Infection and Critical Care

Volumn 63, Issue 1, 2007, Pages 147-157

  McDaniel, D Olga ^a   Hamilton, James ^a   Brock, Marjolyn ^a   May, Warren ^b   Calcote, Lynn ^a,c   Tee, Lee Y ^a   Vick, Laura ^a,c   Newman, D Brian ^a   Vick, Kenneth ^a,c   Harrison, Sebron ^a   Timberlake, Gregory ^a,c   Toevs, Christine ^a,c  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c GV (Sonny) Montgomery Veterans Affairs and Administration Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

AFRICAN AMERICAN; ARTICLE; ASEPSIS; CAUCASIAN; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INFECTION RISK; INJURY; INJURY SCALE; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEPSIS; STATISTICAL ANALYSIS;

AFRICAN AMERICANS; CYTOKINES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENOTYPE; HUMANS; INJURY SEVERITY SCORE; MALE; PATIENT SELECTION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEPSIS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; WOUNDS AND INJURIES;

EID: 34447340572     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e31806bf0ab     Document Type: Article

References (54)

1. Cohen J. The immunopathogenesis of sepsis. Nature. 2000;420:885-891.
2. Angela MK, Faist E. Clinical review: immunodepression in the surgical patient and increased susceptibility to infection. Crit Care. 2002;6:298-305.
3. Ayala A, Ertel W, Chandry IH. Trauma-induced suppression of antigen presentation and expression of major histocompatability class II antigen complex in leukocytes. Shock. 1996;5:79-90.
4. Holmes CL, Russell JA, Walley KR. Genetic polymorphisms in sepsis and septic shock. Role in prognosis and potential for therapy. Chest. 2003;124:1103-1115.
5. Liewelyn M, Sriskandan S, Peakman M, et al. HLA class II polymorphisms determine responses to bacterial superantigens. J Immunol. 2004;172:1719-1726.
6. Parker LC, Whyte MKB, Dower SK, Sabroe I. The expression and roles of Toll-like receptors in the biology of the human neutrophil. J Leukoc Biol. 2005;77:1-7.
7. Frankenfield D, Cooney RN, Smith S. Rowe WA. Age-related differences in the metabolic response to injury. J Trauma. 2000;48:49-57.
8. American College of Chest Physicians-Society of Critical Care Medicine. Consensus Conference. definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-875.
9. Delong WG, Born CT. Cytokines in patients with polytrauma. Clin Orthop Relat Res. 2004;422:57-64.
10. Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anesth. 1996;77:110-117.
11. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor-α promoter on transcriptional activation. Proc Natl Acad Sci USA. 1997;94:3195-3199.
12. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-γ, interleukin-10, transforming growth factor-β1 and tumour necrosis factor-α genes: a technical report. Transpl Immunol. 1998;6:193-197.
13. Rivera-chavez FA, Peters DL, Wheeler HT, O'Keefe GE. The single nucleotide polymorphism (G→C) at the -174 position in the interleukin-6 gene is associated with LPS-stimulated cytokine production. Shock. 2001;15(Suppl):23.
14. Tang GJ, Huang SL, Yien JW, et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med. 2000;28:2733-2736.
15. O'Keefe GE, Hybki DL, Munford RS. The G→A single nucleotide polymorphism at the -308 position in the tumor necrosis factor-α promoter increases the risk for severe sepsis after trauma. J Trauma. 2002;52:817-826.
16. Hildebrand F, Pape H-C, van Griensven M, et al. Genetic predisposition for a compromised immune system after multiple trauma. Shock. 2005;24:518-522.
17. Stassen NA, Leslie-Norfleet LA, Robertson AM, Eichenberger MR, Polk HC Jr. Interferon-gamma gene polymorphisms and the development of sepsis in patients with trauma. Surgery. 2002;132:289-292.
18. Lu KC, Jarmillo A, Lecha RL, et al. Interlukin-6 and interferon-g gene polymorphisms in the development of bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2002;74:1297-1302.
19. Jackson Y, Moore CK, Barker A, et al. Impact of AIF-1 and IL-18 gene polymorphisms on coronary vasculopathy after cardiac transplantation. MAS. 2007;52:94.
20. Takeda K, Akira S. Regulation of innate immune responses by Toll-like receptors. Jpn J Infect Dis. 2001;54:209-219.
21. Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol. 2002;169:4697-4701.
22. Akira S, Sato S. Toll-like receptors and their signaling mechanisms. Scand J Infect Dis. 2003;35:555-562.
23. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 1999;274:10689-10692.
24. Qureshi ST, Lariviere L, Leveque G, et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med Biol. 1999;189:615-625.
25. Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infectious Diseases. 2002;186:1522-1525.
26. Török HP, Glas J, Tonenchi L, Mussack T, Folwaczny C. Polymorphisms of the lipopolysaccharide-signaling complex in inflammatory bowel disease: association of a mutation in the Toll-like receptor 4 gene with ulcerative colitis. Clin Immunol. 2004;112:85-91.
27. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res. 1976;3:2303-2308.
28. McDaniel DO, Yamout S, Aru G, et al. Cytokine genes associated with CV following transplantation. In: International Proc Immunol. Medimond S.r.l.: Bologna, Italy. 2004;493-499.
29. McDaniel DO, Barber WH, Nguyan C, et al. Combined analysis of cytokine genotype polymorphism and the level of expression with allograft function in African American renal transplant patients. Transpl Immunol. 2003;11:107-119.
30. Carrigan SD, Scott G, Tabrizian M. Toward resolving the challenges of sepsis diagnosis. Clin Chem. 2004:1301-1314.
31. Pravica V, Asderakis A, Perrey C, Hajeer A, Sinnott PJ, Hutchinson IV. In vitro production correlates with CA repeat polymorphism in the human IFN-γ gene. Eur J Immunogenet. 1999;26:1-3.
32. Harding D, Dhamrait S, Millar A, et al. Is interleukin-6-174 genotype associated with the development of septicemia in preterm infants? Pediatrics. 2003;112:800-803.
33. Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med. 1999;27:1262-1264.
34. Gebhard F, Pfetsch H, Steinback G, Strecker W, Kinzl L, Bruckner UB. Is interleukin-6 an early marker of injury severity following major trauma in humans. Arc Surg. 2000;135:291-295.
35. Giannoudis PV, Smith MR, Evans RT, Bellamy MC, Guillou PJ. Serum CRP and IL-6 levels after trauma. Not predictive of sepsis complications. Acta Ortho Scand. 1998;69:184-188.
36. Mira JP, Cariou A, Grall F, et al. Association of TNF2-9, TNF-a promoter polymorphism with septic shock susceptibility and mortality. JAMA. 1999;282:561-568.
37. Reid CL, Perry C. Pravica V, Hutchinson IV, Campbell IT. Genetic variation in proinflammatory and anti-inflammatory cytokine production in multiple organ dysfunction syndrome. Crit Care Med. 2002;30:2216-2221.
38. Stuber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-a concentrations and outcome of patients with severe sepsis. Crit Care Med. 1996;24:381-384.
39. Shu Q, Fang X, Chen Q, Stuber F. IL-10 polymorphism is associated with increased incidence of sever sepsis. Chin Med J. 2003;116:1756-1759.
40. Schröder O, Laun R-A, Held B, Ekkernkamp A, Schulte K-M. Association of interleukin -10 promoter polymorphism with the incidence of multiple organ dysfunction following major trauma: results of a prospective pilot study. Shock. 2004;21:306-310.
41. Gallagher PM, Lowe G, Fitzgerald T, et al. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax. 2003;58:154-156.
42. McDaniel DO, Roten DP, Yamout SZ, et al. Cytokine gene polymorphism might affect the outcome of clinical rejection in cardiac transplantation. J Appl Res. 2004;4:68-80.
43. Sankaran D, Asderakis A, Ashraf S, et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Internat. 1999;56:281-288.
44. Richard SM, Cue JI, Goddard JK, Parramore JB, DiPiro JT. Interleukin-10 is associated with the development of sepsis in trauma patients. J Trauma. 1996;40:613-617.
45. Karni A, Koldzic DN, Bharanidharan P, Khoury S, Weiner HL. IL-18 is linked to raised IFN-γ in multiple sclerosis and is induced by activated CD4+ T cells via CD40-CD40 ligand interactions. J Neuroimmunol. 2002;125:134-140.
46. Oberholzer A, Steckholzer U, Kurimoto M, Trentz O, Ertel W. Interleukin-18 plasma levels are increased in patients with sepsis compared to severely injured patients. Shock. 2011;16:411-414.
47. Emmanuilidis K, Weighardt H, Matervossian E, et al. Differential regulation of systemic IL-18 and IL-12 release during postoperative sepsis: high serum IL-18 as an early predictive indicator of lethal outcome. Shock. 2002;18:301-305.
48. McAdam BF, Mardini IA, Habib A, et al. Effect of regulated expression of human cylooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest. 2000;105:1473-1482.
49. Bonita IL, Parnham MJ. Immunomodulatory-antiinflammatory functions of E-type prostaglandins. Minireview with emphasis on macrophage mediated effects. Int J Immunopharmacol. 1982;4:103-109.
50. Faist E, Mewes A, Baker CC, et al. Prostaglandin E2 dependent suppression of interleukine-2 production in patients with major trauma. J Trauma. 1987;27:837-848.
51. Netea MG, Van der Meer JWM, Kulberg B-j. Toll-like receptors as an escape mechanism from the host defense. Trends Microbiol. 2004;12:484-488.
52. Van Amersfoort ES, Van Berkel TJ, Kuiper J. Receptor, mediators and mechanisms involved in bacterial sepsis and septic shock. Clin Microbial Rev. 2003;16:379-414.
53. Texereau J, Chiche J-D, Taylor W, Choukroun G, Comba B, Mira J-P. The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin Inf Dis. 2005;41:S408-S415.
54. Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J. Development and validation of multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem. 2006;52:1284-1293.